Respiratory syncytial virus (RSV) is a leading cause of infant mortality, and there are currently no licensed vaccines to protect this vulnerable population. A comprehensive understanding of infant antibody responses to natural RSV infection would facilitate vaccine development. Here, we isolated more than 450 RSV fusion glycoprotein (F)-specific antibodies from 7 RSV-infected infants and found that half of the antibodies recognized only two antigenic sites. Antibodies targeting both sites showed convergent sequence features, and structural studies revealed the molecular basis for their recognition of RSV F. A subset of antibodies targeting one of these sites displayed potent neutralizing activity despite lacking somatic mutations, and similar antibodies were detected in RSV-naive B cell repertoires, suggesting that expansion of these B cells in infants may be possible with suitably designed vaccine antigens. Collectively, our results provide fundamental insights into infant antibody responses and a framework for the rational design of age-specific RSV vaccines.
INTRODUCTION
Respiratory syncytial virus (RSV) is a ubiquitous pathogen that causes bronchiolitis and pneumonia in infants and the elderly, resulting in nearly 60,000 in-hospital deaths annually in children under the age of 5 (Shi et al., 2017) . Currently, the only preventive measure available for RSV is passive prophylaxis with the monoclonal antibody Synagis (The IMpact-RSV Study Group, 1998) . Unfortunately, prophylaxis with Synagis is costly and requires multiple doses per RSV season (Homaira et al., 2014; Kamal-Bahl et al., 2002) , thereby restricting its use to high-risk infants in developed countries. Therefore, the development of an effective RSV vaccine and next-generation monoclonal antibodies is of great importance and ongoing clinical trials are evaluating numerous candidates (PATH, 2017 ).
An effective RSV vaccine has remained elusive due in part to the young age at which primary infection occurs (Glezen et al., 1986) , a history of vaccine-enhanced disease in infants (Acosta et al., 2015) , and a lack of long-lived immunity that results in frequent reinfections throughout life (Hall et al., 1991) . Five target age groups for vaccination have been proposed-infants under 6 months of age, infants over 6 months of age, school-aged children, pregnant women, and adults over 65 years old-with the goal of either directly or indirectly protecting at-risk populations (Anderson et al., 2013) . These target age groups have different immunological characteristics that may require different vaccination strategies for optimal protection. Although multiple modalities for an RSV vaccine are currently being pursued, most vaccination strategies seek to elicit neutralizing antibodies that recognize the RSV fusion glycoprotein (RSV F), which is targeted by the majority of RSV-neutralizing activity in human sera (Sastre et al., 2005) .
RSV F is a class I fusion protein that mediates viral entry into host cells by converting from a metastable trimeric prefusion conformation (preF) to a highly stable postfusion conformation (postF). The antigenic topology of RSV F is substantially altered during this transition. Some groups of epitopes, referred to as antigenic sites, are generally conserved on both preF and postF, whereas others are found primarily on only one of the conformations (Graham, 2017) . Molecules that prevent these structural changes can prevent viral fusion and have potential as therapeutics for RSV (Battles et al., 2016; Huang et al., 2010; Lambert et al., 1996; McLellan et al., 2013) .
The first characterized RSV F-reactive antibodies bound to structural elements shared by both preF and postF and were therefore F-conformation independent. These antibodies include Synagis, which recognizes antigenic site II (Beeler and van Wyke Coelingh, 1989; McLellan et al., 2010b) , and 101F, which recognizes antigenic site IV (McLellan et al., 2010a; Wu et al., 2007) . Antibodies that preferentially bind to antigenic site I on postF were also readily isolated, but these were only weakly neutralizing (Anderson et al., 1986; García-Barreno et al., 1989) . The first preF-specific antibodies to be described recognized antigenic site Ø (''zero''), present at the apex of the preF trimer, and were extremely potent (McLellan et al., 2013) . A second class of potently neutralizing antibodies, epitomized by MPE8, was later described and shown to recognize antigenic site III (Corti et al., 2013) . Although the secondary structure elements that form site III are present on both preF and postF, they adopt a different spatial arrangement in postF that results in higher-affinity binding to preF (Corti et al., 2013) . Antigenic site V, located between sites Ø and III, was recently identified and shown to be the target of additional preF-specific antibodies that are potently neutralizing (Gilman et al., 2016; Mousa et al., 2017) . A preF-specific antibody that targets site Ø and contains Fc modifications to extend serum half-life (MEDI8897) is currently in late-phase clinical trials (Griffin et al., 2017; Zhu et al., 2017 ).
An effective RSV vaccine will likely require the elicitation of potent neutralizing antibodies and a well-balanced T helper 1 (Th1) and Th2 cell response (Lambert et al., 2014; Legg et al., 2003) . Infants present a number of unique challenges for vaccine development, including suppression of B cell responses by maternally derived antibody and immunological immaturity that results in reduced levels of T cell help, antibody classswitching, and somatic hypermutation (SHM) (Siegrist and Aspinall, 2009 ). Studies of convalescent infant sera have demonstrated that infants generally produce low titers of RSV-neutralizing antibodies after infection (Esposito et al., 2016; Murphy et al., 1986; Sande et al., 2014) , although these titers are higher when levels of maternal antibody are low (Shinoff et al., 2008) , suggesting that infants are capable of mounting neutralizing antibody responses to RSV. Serum studies have also suggested that different epitopes may be targeted as children age into adulthood (Fuentes et al., 2016) , but little is known about how these changes are associated with antibody sequence or neutralization potency. An improved understanding of the specificities and neutralizing activities of antibodies induced by RSV infection in infants could facilitate the design of vaccine antigens that are less susceptible to interference by maternal antibody and that focus the response on epitopes associated with neutralizing activity.
Here, we sought to characterize the infant antibody response to mature, processed RSV F by isolating over 450 RSV F-specific antibodies from the peripheral B cells of seven RSV-infected infants. Infant responses were biased toward recognition of a limited number of antigenic sites that are distinct from those that dominate adult responses. Recognition of one of these sites was mediated by non-neutralizing antibodies that contained a convergent complementarity-determining region (CDR) H3 motif. A second site was recognized by antibodies that predominately utilized IGHV3-21:IGLV1-40 gene pairing, a subset of which displayed neutralizing activity despite lacking somatic mutations, suggesting that it may be possible to induce protective antibody responses in very young infants. Structural studies revealed the molecular basis for the conserved features of antibodies recognizing both sites, providing a blueprint for the rational design of vaccine immunogens capable of stimulating neutralizing antibody responses in young infants.
RESULTS

RSV F-Specific Antibodies Isolated from Young Infants Have Low Levels of SHM and Biased V-Gene Usage
To analyze infant B cell responses to RSV F, we obtained blood samples from seven infants that were hospitalized due to complications associated with RSV infection. Of the seven infants, five were < 3 months and two were R 6 months of age at the time of hospitalization (Table S1 ). The youngest three infants were also %3 months at the time of blood draw. Six out of the seven infants were infected during the first RSV season of their life and were therefore probably experiencing a primary infection. One donor was 29.5 months old at the time of blood draw but was also likely experiencing a primary infection because secondary RSV infections generally do not result in hospitalization (Glezen et al., 1986) . To assess the magnitude of the B cell response to RSV F, peripheral blood mononuclear cells (PBMCs) were stained with fluorescently labeled tetramers of preF and postF trimers and analyzed by flow cytometry (Figures S1A and S1B). As expected, the frequency of class-switched B cells that were RSV F specific was substantially lower in infants <3 months compared with infants R6 months ( Figure S1C ). In infants <3 months, the frequency of RSV F-specific classswitched B cells ranged from 0.05% to 0.3%, whereas in infants R6 months, the frequency ranged from 1.2% to 1.6%. Between 100 and 300 RSV F-reactive B cells from each donor were singlecell sorted and the antibody variable heavy (VH)-and variable light (VL)-chain sequences were rescued by single-cell PCR (Tiller et al., 2008) . Due to the low frequency of RSV F-specific class-switched B cells in the five younger infants, all B cells that reacted with RSV F were single-cell sorted ( Figure 1A ). For the two infants that were R6 months, only class-switched B cells were sorted ( Figure 1B) . Although all B cells that reacted with RSV F were sorted from infants <3 months, index sorting allowed for the determination of the B cell surface markers expressed on each sorted cell and revealed that 14%-60% of the RSV F-specific B cells sorted from infants <3 months were class-switched and/or CD27 + , with the remaining B cells lacking classical memory markers ( Figure 1C ).
In total, more than 450 cognate VH and VL pairs were cloned and expressed as full-length immunoglobulin Gs (IgGs). As expected, sequence analysis showed that the median level of SHM in antibodies isolated from class-switched B cells increased as a function of age ( Figure 1D) . Also, the majority of antibodies isolated from the youngest three infants lacked SHM, similar to what was observed previously in postF-reactive B cells (Williams et al., 2009 ). However, nearly 5% of antibodies isolated from these infants had VH genes containing at least five nucleotide substitutions, consistent with previous studies showing that SHM does occur in young infants, albeit at relatively low frequency (Rechavi et al., 2015; Ridings et al., 1998) . The level of SHM in antibodies isolated from the two infants R6 months was relatively high, with a median of 7 and 13 VH nucleotide substitutions, respectively ( Figure 1D ). Analysis of V-gene usage showed that RSV F-reactive infant antibody responses were strongly biased toward either IGHV3-21:IGLV1-40 or the highly related IGHV3-11:IGLV1-40 gene pairing ( Figure 1E ). There was also a more modest preference for the IGHV1-18:IGKV2-30, IGHV1-18:IGLV3-21, and IGHV5-51:IGLV6-57 gene pairs ( Figure 1E ). The IGHV1-18:IGKV2-30 gene pair was present in 8.5% of RSV F-reactive antibodies isolated from adults and is associated with recognition of site V on preF (Gilman et al., 2016; Mousa et al., 2017) . Overall, the results demonstrate that RSV infection induces B cell responses with higher levels of SHM in infants R6 months compared to <3 months and that the responses in both age groups exhibit biased V-gene usage.
A Subset of Infant Antibodies Binds with High Affinity to RSV F and Potently Neutralizes RSV We next determined the apparent (IgG) binding affinity of each antibody for preF and postF. For the infants <3 months, 24%-33% of the isolated antibodies bound to preF with affinities %5 nM compared with 45% and 91% for the two infants R6 months (Figure 2A , medium and high). Although a total of 40 antibodies with preF affinities %5 nM were isolated from the youngest three infants, only two antibodies with %5 nM affinity for postF were isolated from these three infants ( Figure 2B ). In addition, the percentage of characterized antibodies from each infant that were preF specific ranged from 41% to 100%, whereas substantially smaller percentages (0%-18%) were postF specific ( Figure S2A ). Antibodies recognizing both preF and postF comprised about 27%-47% of the characterized antibody responses in the four oldest infants, but less than 10% of the response in the three youngest infants. Collectively, these results suggest that young infants generate a preF-biased antibody response that expands to include recognition of postF as infants age.
The antibodies were also tested for neutralizing activity using a high-throughput assay modified from a previously established flow-cytometry assay (Chen et al., 2010) . This analysis revealed that 11%-50% of the antibodies isolated from each infant had measurable neutralizing activity (IC 50 < 100 mg/mL), and a subset of antibodies isolated from six out of the seven infants showed highly potent neutralizing activity (IC 50 % 0.05 mg/mL) ( Figure 2C ). Nearly 20% of the neutralizing antibodies lacked V-gene mutations (Table S2 ), suggesting that affinity maturation is not required for neutralization of RSV. However, the proportion of antibodies with medium-to-high neutralizing activity (IC 50 % 0.5 mg/mL) was about 3.5 times higher in the group of antibodies that contained SHM compared to those that lacked SHM, suggesting that affinity maturation does improve the overall response ( Figure S2B ). Analysis of the relationship between binding affinity and neutralization potency demonstrated that most highly potent neutralizing antibodies bound with high affinity to preF (K D % 0.5 nM) and failed to bind to postF ( Figure 2D ). In addition, although approximately 20% of the neutralizing antibodies isolated from infants R6 months recognized both preF and postF, this type of neutralizing antibody was rare in infants <3 months (Figures 2D and S2C) , demonstrating that nearly all neutralizing antibodies in very young infants are preF specific.
We next assessed the polyreactivity of the infant antibodies using a previously described assay (Jain et al., 2017) . Although the fraction of medium-to-highly polyreactive antibodies was relatively low for all infants (%15%), there was a higher proportion of polyreactive antibodies in the infants <3 months compared to the infants R6 months ( Figure S3A ). This result could be related to differences in tolerance mechanisms in these two infant populations or to the higher frequency of antibodies lacking SHM in the younger infants. In support of the latter See also Figure S1 and Table S2. hypothesis, stratification of the antibodies based on their SHM levels showed that 12% of antibodies that lacked SHM displayed medium-to-high polyreactivity, compared with <2% of antibodies that contained >5 VH gene substitutions ( Figure S3B ). This is consistent with a prior study showing that the process of affinity maturation can result in decreased polyreactivity of human antibodies (Reed et al., 2016) .
Infant Antibody Responses Are Focused Primarily on Two Antigenic Sites that Have Different Neutralization Sensitivities
To define the epitopes recognized by the infant antibodies, each antibody was tested for competition with a panel of known RSV F-specific antibodies and assigned to an antigenic site based on the competition profile ( Figures 3A and 3B ). In the three youngest infants, responses were dominated by antibodies directed against site III, whereas in the other infants a larger proportion of the responses were directed against site I, and in some cases site IV ( Figure 3B ). The proportion of antibodies recognizing preF-specific sites Ø and V at the apex of the preF molecule was low, particularly in the three youngest infants. Interestingly, analysis of the V-gene usage for the site I-directed antibodies revealed that more than 25% utilized the IGKV1-39 light chain gene ( Figure S4A ). Although these site I-directed antibodies utilized a variety of VH genes, many possessed a convergent CDR H3 motif, generated from recombination of the IGHD3-22 and IGHJ-4 genes ( Figure S4B ). In contrast, nearly 85% of antibodies that recognized site III utilized either the IGHV3-21:IGLV1-40 or the related IGHV3-11:IGLV1-40 gene pairing ( Figure S4C ) and did not show evidence of a convergent CDR H3 sequence ( Figure S4B ). The majority of site III-directed antibodies were preF specific and nearly 50% had medium-to-high neutralizing activity, whereas antibodies that recognized site I preferentially bound to postF and tended to be weakly or non-neutralizing ( Figures  3C, S4D , and S4E). In infants <3 months, 60% of antibodies that displayed high neutralizing activity (IC 50 % 0.05 mg/mL) were directed against site III ( Figure 3C ). Therefore, although antibodies against both sites I and III are readily elicited during RSV infection in infants, site III-directed antibodies can potently neutralize RSV whereas site I-directed antibodies are typically non-neutralizing.
Site III-Directed Antibodies Can Neutralize RSV in the Absence of SHM and Are Present in the Naive B Cell Repertoire We next analyzed the epitope specificities of the neutralizing antibodies that lacked SHM ( Figure 4A ). Of the 33 germline See also Figure S2 and Table S2. antibodies that displayed detectable RSV-neutralizing activity, 27 targeted antigenic site III. Analysis of the index sort data revealed that approximately half of the neutralizing germline antibodies originated from naive B cells (IgG Figure 4B ). The identification of site III-directed neutralizing antibodies from naive B cells led us to investigate the occurrence of these antibody specificities in the naive B cell repertoire. We therefore cloned and expressed 112 and 19 antibodies from RSV F-reactive cord blood B cells and healthy adult naive B cells, respectively. Due to the low affinity of naive B cell-derived antibodies, only 22/112 (20%) antibodies isolated from cord blood B cells and 9/19 (47%) antibodies isolated from adult naive B cells bound with measurable affinity to RSV F as full-length IgGs. However, 11/22 (50%) and 7/9 (78%) of the RSV F-binding antibodies isolated from cord blood and adult naive B cells, respectively, utilized IGHV3-21:IGLV1-40 or IGHV3-11:IGLV1-40 gene pairing ( Figure 4C ). Of these 18 antibodies, the 13 with binding affinities that allowed for analysis in a competition assay were all shown to recognize antigenic site III (Table S3 ). The affinities of these antibodies for preF were relatively high, ranging from 1.0 to 60 nM ( Figure 4C ). In addition, approximately 40% of these site III-directed antibodies were neutralizing, with IC 50 values ranging from 1.5 to 4.4 mg/mL ( Figure 4C ). In contrast, none of the naive B cell-derived antibodies that utilized other V-gene combinations showed detectable neutralizing activity ( Figure 4C ). Collectively, these results indicate that site IIIdirected antibodies can neutralize RSV in the absence of SHM and that these types of antibodies are present in the naive B cell repertoire. Table S4 ; Krarup et al., 2015) . This antibody was potently neutralizing despite lacking SHM (Table S2 , Figure S5B ). The structure revealed that although the heavy chain accounts for roughly 65% of the buried surface area on preF, light chain residues Tyr31 (Kabat numbering) in CDR L1 and Tyr91 in CDR L3 are likely important and contact the loop connecting a6 to a7 on preF ( Figure 5B ). Consistent with our structural analysis, substitution of Tyr31 or Tyr91 with alanine resulted in greater than 200-or 80-fold reductions in affinity, respectively, as measured by surface plasmon resonance (SPR) ( Figure 5C ).
In addition to the contacts formed by the light chain, the CDR H2 encoded by IGHV3-21 contains a stretch of five consecutive serine residues, three of which are near Asp310 on b6 of preF and could form hydrogen bonds with this residue. The IGHV3-11 and IGHV3-48 genes, which share a high degree of sequence identity with IGHV3-21, were utilized by site III-directed antibodies at a much lower frequency than IGHV3-21. One explanation for this could be the presence of a tyrosine residue (Tyr56) directly following the polyserine motif in IGHV3-21. Our structure shows that Tyr56 of ADI-19425 is buried in a small groove neighboring antigenic site II on preF ( Figure 5B ). This tyrosine is not present in IGHV3-48 and is present in only some alleles of IGHV3-11. Although we isolated three site III-directed antibodies that utilized either IGHV3-48 or IGHV3-11 and contained a threonine at position 56 (ADI-19461, ADI-22776, and ADI-19440) , these had low affinity for preF and were non-neutralizing (Table S2) . Consistent with these observations, substitution of Tyr56 with alanine resulted in a more than 9-fold decrease in affinity to preF ( Figure 5C ).
In contrast to the V-gene-specific features highlighted above, there were fewer restrictions on the sequences of the CDR H3s of site III antibodies that utilized IGHV3-21:IGLV1-40 or IGHV3-11:IGLV1-40 gene pairing. The CDR H3s varied from 10 to 20 amino acids in length with some preference toward usage of glycine, serine, and tyrosine residues at positions 96-100c (Figure S4B) . Our structure reveals that although the ADI-19425 CDR H3 buries approximately 250 Å 2 on preF, it does not form hydrogen bonds or salt bridges with either protomer ( Figure 5B ). See also Figure S3 and Table S2 .
Notably, the neutralizing antibody MPE8, which has recently been structurally characterized (Wen et al., 2017) , also utilizes the IGHV3-21 and IGLV1-40 gene pair to recognize site III with a binding mode nearly identical to that of ADI-19425, despite a substantially different CDR H3 ( Figures S5C and S5D ). This is consistent with our observation that multiple CDR H3 sequences can be utilized by this family of antibodies to recognize preF.
A Site I-Directed Non-neutralizing Antibody Recognizes PostF using a Convergent CDR H3 Motif and GermlineEncoded Regions of the IGKV1-39 Light Chain
We determined the 3.0 Å resolution structure of a site I-directed antibody, ADI-14359, in complex with postF to define the molecular determinants of the convergent antibody features ( Figure 6A , Table S4 ). The structure revealed that the 18-amino-acid long CDR H3, generated from the convergent usage of IGHD3-22/IGHJ-4, is partially inserted into a small groove near the top of the postF trimer ( Figure 6B ) and makes a number of hydrogen bonds with postF residues in and around this groove ( Figure 6C ). CDR H3 residues Tyr100c and Tyr100d, which are uncommon in IGHD genes other than IGHD3-22, form hydrogen bonds with postF residues Glu31 and Glu378, respectively, which are located on the ridge surrounding the groove. The tip of the CDR H3 loop is composed of three small amino acids that allow it to stack against Trp314, which is positioned at the floor of the groove. These small residues also make hydrogen bonds with residues Asp344 and Asn380 of postF. In addition, heavy chain residue Tyr100g, which is unique to the IGHJ-4 gene, stacks against Tyr49 in the light chain, which may help properly orient the CDR H3. Antibodies that utilized the convergent CDR H3 were biased toward pairing with the IGKV1-39 light chain gene. Several germline-encoded residues within CDR L1 and the framework region 3 (FR3) of IGKV1-39 form hydrogen bonds with Glu31 on postF ( Figure 6C ). This region of the light chain of ADI-14359 is predicted to clash substantially with b22 of preF, which rearranges during the transition to postF ( Figure S6 ). Therefore, preferential binding to postF by this type of antibody appears to be mediated by the light chain. In addition, Tyr92 at the start of the CDR L3 is a unique feature of IGKV1-39 and forms a hydrogen bond with Ser35 on postF. These features, combined with the interaction of Tyr49 of IGKV1-39 with Tyr100g of the CDR H3, may help to explain the preferential usage of IGKV1-39 by this group of antibodies.
Although site I-directed antibodies did not show convergent VH-gene usage, the heavy chain utilized by ADI-14359 also makes critical interactions with postF ( Figure 6C ). Arg50 forms a salt bridge with Asp52 in the CDR H2 and appears to aid in coordinating an electrostatic interaction between Asp52, Asp54, and Asp56 of the CDR H2 with Lys390 on postF. Arg50 also forms a hydrogen bond with light-chain residue Tyr96, which is unique to the IGKJ2 gene utilized by ADI-14359. To investigate the contribution of these VH-gene-mediated interactions to binding, we generated an R50L variant of ADI-14359, since a leucine is present at position 50 in other alleles of IGHV2-70. The affinity of the R50L variant for postF was reduced by more than 30-fold as measured by SPR ( Figure 6D ). In addition, substitution of Lys390 with alanine (K390A) on postF almost entirely ablated ADI-14359 binding ( Figure 6D ). The presence of three acidic residues in the CDR H2 therefore appears to be critical for the interaction of ADI-14359 with postF. However, the contribution of the CDR H2 to binding may vary among other members of this group, since many of the VH germlines utilized lack this acidic motif.
DISCUSSION
Our results demonstrate that infant antibody responses to RSV F differ substantially from those of healthy adults, not only in See also Figure S4 , Tables S2 and S3. affinity and neutralization potency, but also in the patterns of epitope recognition. The infant responses were focused on two major regions of the RSV F trimer-antigenic sites I and IIIneither of which are dominant in adult responses (Gilman et al., 2016) . These differences were the most extreme in infants under 3 months of age, with infants older than 6 months exhibiting responses that began to resemble healthy adults. This observation is consistent with previous studies showing that the infant immune system begins to mature at around 6 months of age (Ridings et al., 1998) . The majority of antibodies that recognized antigenic site III utilized the same V-gene pairing but were not restricted in Dand J-gene usage. A subset of these antibodies showed potent neutralizing activity despite lacking SHM. Recent work has shown that polyclonal IgM antibodies purified from RSV-naive infant sera are capable of neutralizing RSV, and it was suggested that these antibodies may represent natural anti-RSV antibodies that react with the N-and O-linked glycans present on the RSV surface glycoproteins (Jans et al., 2017) . However, unlike natural IgM antibodies-which rely on avidity, typically recognize common surface antigens, and exhibit some degree of polyreactivity (Panda and Ding, 2015) -the site III-directed antibodies described here bound with high affinity in an IgG backbone, specifically recognized an epitope on RSV F that lacks N-linked glycans, and generally showed little to no polyreactivity, suggesting that they are distinct from previously described natural IgM antibodies. Similar germline-mediated recognition in the adaptive immune response has also been described for other viral pathogens, including hepatitis C virus (Bailey et al., 2017) and human cytomegalovirus (Thomson et al., 2008) , and for bacterial pathogens such as Staphylococcus aureus (Yeung et al., 2016) . The presence of functional germline antibodies in the human antibody repertoire has been proposed to serve as a type of innate humoral response to See also Figure S5 and Table S4 .
life-threatening pathogens that are likely to be encountered early in life (Lerner, 2011) . The isolation of this class of antibodies from all seven infants studied here, as well as from cord blood B cells, adult naive B cells, and memory B cells from previously characterized adult donors (Gilman et al., 2016) , suggests that the naive B cell precursors encoding these antibody specificities are likely present in most individuals and that these B cells can be activated in response to antigen exposure and undergo affinity maturation. This is in contrast to HIV broadly neutralizing antibodies, which develop in only a subset of infected individuals and whose inferred germline precursors display limited reactivity with native HIV envelope antigens (Burton and Hangartner, 2016) . Although further studies will be required to determine the levels and function of these antibodies in infant sera and elucidate their role in protection from severe RSV disease, our results suggest that expansion of these cells may be a feasible goal for infant vaccination strategies. Neutralizing antibodies that react with both preF and postF were identified in healthy adults and infants over 6 months old but were almost entirely absent in the youngest infants analyzed here. Although postF antigens are capable of eliciting neutralizing antibodies that also bind to preF, their inability to elicit preF-specific antibodies would likely prove problematic for use in a young infant population. In addition, our results show that a relatively large fraction of the infant antibody response is directed against antigenic site I, which is well exposed on postF. Antibodies targeting this site generally See also Figure S6 and Table S4. lacked neutralizing activity, suggesting that vaccination with postF antigens could drive infant antibody responses toward ineffective recognition of RSV F. Formalin-inactivated RSV (FI-RSV), the preparation that resulted in vaccine-enhanced disease in infants in the 1960s, displays an abundance of postF on the surface of the virus (Killikelly et al., 2016) . Although many factors contribute to the development of vaccine-enhanced disease (Acosta et al., 2015) , our data suggest that the high abundance of postF on FI-RSV could result in the induction of high levels of site I-directed antibodies and a low fraction of neutralizing antibodies, which is a property associated with the formation of immune complexes that contribute to lung pathology in vaccine-enhanced illness (Murphy and Walsh, 1988; Polack et al., 2002) . We observed an age-dependent increase in the response against antigenic sites Ø and V, which are both present near the apex of the preF trimer. Although infant antibodies that targeted these epitopes tended to be potently neutralizing, they were present at low abundance, particularly in infants under 3 months of age. These data suggest that although the presence of site Ø is likely important for generating neutralizing antibody responses later in life, eliciting a neutralizing response in young infants may depend on the presentation of antigenic site III. These differences in the dominant epitopes targeted by infant and adult responses provide a unique opportunity for prevention strategies that seek to combine passive and active immunization. For example, vaccines could be designed to preferentially elicit site III antibodies, which would not compete for binding with second-generation prophylactic antibodies that target antigenic site Ø, such as MEDI8897 (Griffin et al., 2017; Zhu et al., 2017) . In addition, antibodies elicited by a site-III-specific vaccine would not block access to the apex of the preF trimer on infectious virions, allowing the development of neutralizing antibodies directed against antigenic sites in this region to occur during RSV infection.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: the StrepTactin resin therefore contained trimers with two StrepTagII trimers and one 6x His-tag-AviTag trimer. These proteins were then biotinylated using birA (Avidity) and then separated from excess biotin by size-exclusion chromatography on a Superdex 200 column (GE Healthcare) in PBS.
Single B cell sorting PBMCs from RSV-infected infants were stained using anti-human IgG (BV605), IgA (FITC), CD27 (BV421), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD3 (PerCP-Cy5.5), CD19 (PECy7), CD20 (PECy7) and a mixture of dual-labeled preF and postF tetramers (50 nM each). For infants R 6 months of age, class-switched B cells binding to RSV F tetramers were single-cell sorted. For infants < 3 months of age, total B cells binding to RSV F tetramers were single-cell sorted. For naive B cell sorting, cord blood or PBMCs from healthy adult donors were stained with anti-human IgG (BV605), IgM (FITC), CD27 (BV421), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD19 (PECy7), CD20 (PECy7), CD21 (APC-Cy7) and a mixture of dual-labeled preF and postF tetramers (50 nM each). CD8 Single B cell cloning Antibody variable genes (IgH, Igl and Igk) were amplified by RT-PCR and nested PCR reactions using cocktails of IgG-, IgM-, and IgA-specific primers (Tiller et al., 2008) . The primers used in the second round of PCR contained 40 base pairs of 5ʹ and 3ʹ homology to the digested expression vectors to allow for cloning by homologous recombination into Saccharomyces cerevisiae (Swers et al., 2004) . PCR products were cloned into S. cerevisiae using the lithium acetate method for chemical transformation (Gietz and Schiestl, 2007) . Each transformation reaction contained 10 mL of unpurified heavy chain and light chain PCR product and 200 ng of cut heavy and light chain plasmids. Following transformation, individual yeast colonies were picked for sequencing and characterization.
Expression and purification of IgGs and Fab fragments RSV F-specific IgGs were expressed in S. cerevisiae cultures grown in 24-well plates. After 7 days, the supernatant was harvested and IgGs were purified with Protein A. IgGs were eluted with 200 mM acetic acid, 50 mM NaCl pH 3.5 into 1/8 th volume 2 M HEPES pH 8.0. IgGs were then buffer exchanged into PBS pH 7.0. Fab fragments used for competition assays were generated by digesting the IgGs with papain for 2 h at 30 C. The digestion was terminated by the addition of iodoacetamide, and the Fab and Fc mixtures were passed over Protein A agarose to remove Fc fragments and undigested IgG. The flowthrough of the Protein A resin was then passed over CaptureSelect IgG-CH1 affinity resin (ThermoFischer Scientific), and eluted with 200 mM acetic acid, 50 mM NaCl pH 3.5 into 1/8 th volume 2 M HEPES pH 8.0. Fab fragments were then buffer exchanged into PBS pH 7.0.
Biolayer interferometry binding analysis
IgG binding affinities for DS-Cav1 and RSV F DFP were measured by BLI using a Forté Bio Octet HTX instrument (Pall Life Sciences). For high-throughput K D determination, IgGs were immobilized on AHQ sensors (Pall Life Sciences) and exposed to 100 nM antigen in PBS containing 0.1% BSA (PBSF) for an association step, followed by a dissociation step in PBSF buffer. Data were analyzed using the Forté Bio Data Analysis Software 7. IgG K D s were calculated for antibodies with BLI responses > 0.1 nm. The data were fit to a 1:1 binding model to calculate association and dissociation rate constants, and K D was calculated using the ratio k d /k a .
Antibody competition assays
Antibody competition was measured by the ability of a control anti-RSV F Fab to inhibit binding of yeast surface-expressed anti-RSV F IgGs to either DS-Cav1 or F DFP. 50 nM biotinylated DS-Cav1 or F DFP was pre-incubated with 1 mM competitor Fab for 30 min at room temperature and then added to a suspension of yeast expressing anti-RSV F IgG. Unbound antigen was removed by washing with PBS containing 0.1% BSA (PBSF). After washing, bound antigen was detected using streptavidin Alexa Fluor 633 at a 1:500 dilution (Life Technologies) and analyzed by flow cytometry using a FACSCanto II (BD Biosciences). The degree of competition was analyzed by measuring the fold reduction in antigen binding in the presence of competitor Fab relative to an antigen-only control. Antibodies that showed a greater than five-fold reduction in binding in the presence of competitor Fab were considered competitors.
Polyreactivity assay
Antibody polyreactivity assay was performed essentially as described previously (Jain et al., 2017) . IgGs presented on the surface of yeast were incubated with biotinylated CHO cell membrane preparations and incubated on ice for 20 minutes. Cells were then washed and re-suspended in secondary antibody mix (Extravidin-R-PE, anti-human LC-FITC, and propidium iodide). The mixture was incubated on ice for 20 minutes and then washed twice with PBSF. Cells were then re-suspended in PBSF and run on a FACSCanto II (BD Biosciences). The mean fluorescence intensities of binding were normalized using control antibodies that display high, medium, or low polyreactivity to assess non-specific binding.
